Mice treated with (MS@OVAinMOF)@(polyICinMOF) plus a low dose of i.p. anti-PD-1 (group f) show a higher survival rate and a smaller tumour volume than those treated with only free OVA (group b), free OVA plus a low dose of i.p. anti-PD-1 (group c), OVAonMS plus a low dose of i.p. anti-PD-1 (group d) and OVA/polyIConMS plus a low dose of i.p. anti-PD-1 (group e). This evidence concerns the gene PDCD1 and neoplasm.